ISV-303

DRUG4 trials

Sponsors

Sun Pharmaceutical Industries Limited

Conditions

CataractOcular Inflammation

Phase 1

Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers

CompletedNCT01190878

Sun Pharmaceutical Industries LimitedOcular Inflammation

Start: 2010-08-31End: 2011-01-31Updated: 2021-11-19

Phase 2

Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery

CompletedNCT01387464

Sun Pharmaceutical Industries LimitedCataract

Start: 2011-07-31End: 2011-08-31Updated: 2021-11-19

Phase 3

Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects

CompletedNCT01576952

Sun Pharmaceutical Industries LimitedOcular Inflammation

Start: 2012-07-31End: 2013-01-31Updated: 2021-11-19

Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects

CompletedNCT01808547

Sun Pharmaceutical Industries LimitedOcular Inflammation

Start: 2013-05-31End: 2013-11-30Updated: 2021-11-19

Related Papers

Twice-Daily vs. Once-Daily Dosing with 0.075% Bromfenac in DuraSite: Outcomes from a 14-Day Phase 2 Study.

2017-08-173 citations